MeCP2-mediated alterations of striatal features accompany psychomotor deficits in a mouse model of Rett syndrome.
Rett Syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene. Affected individuals develop motor deficits including stereotypic hand movements, impaired motor learning and difficulties with movement. To understand the neural mechanisms of motor deficits in RTT, we characterized the molecular and cellular phenotypes in the striatum, the major input nucleus of the basal ganglia that controls psychomotor function, in mice carrying a null allele of Mecp2. These mice showed significant hypoactivity associated with impaired motor coordination and motor skill learning. We found that dopamine content was significantly reduced in the striatum of Mecp2 null mice. Reduced dopamine was accompanied by down-regulation of tyrosine hydroxylase and up-regulation of dopamine D2 receptors, particularly in the rostral striatum. We also observed that loss of MeCP2 induced compartment-specific alterations in the striatum, including reduced expression of μ-opioid receptors in the striosomes and increased number of calbindin-positive neurons in the striatal matrix. The total number of parvalbumin-positive interneurons and their dendritic arborization were also significantly increased in the striatum of Mecp2 null mice. Together, our findings support that MeCP2 regulates a unique set of genes critical for modulating motor output of the striatum, and that aberrant structure and function of the striatum due to MeCP2 deficiency may underlie the motor deficits in RTT.
Institute of Neuroscience, National Cheng-Chi University, 64, Sec. 2, Chi-Nan Road, Wen-Shan District, Taipei, 11605, Taiwan.
Fang-Chi
FC
Kao
San-Hua
SH
Su
Gregory C
GC
Carlson
Wenlin
W
Liao
D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D064026:Calbindins / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000473:pathology*; D004195:Disease Models, Animal; D004298:Dopamine / Q000235:genetics / Q000378:metabolism; D005106:Exploratory Behavior / Q000502:physiology; D005260:Female; D005786:Gene Expression Regulation / Q000235:genetics; D005838:Genotype; D007858:Learning / Q000502:physiology; D008297:Male; D051783:Methyl-CpG-Binding Protein 2 / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D011596:Psychomotor Disorders / Q000209:etiology* / Q000473:pathology*; D012333:RNA, Messenger; D011954:Receptors, Dopamine / Q000235:genetics / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000235:genetics / Q000378:metabolism; D015518:Rett Syndrome / Q000150:complications* / Q000235:genetics*; D045442:Rotarod Performance Test; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics / Q000378:metabolism
D064026:Calbindins; C497393:Mecp2 protein, mouse; D051783:Methyl-CpG-Binding Protein 2; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D011954:Receptors, Dopamine; D017450:Receptors, Opioid, mu; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine